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Abstract
Background: The extension of the interdialytic interval due to due to dialysis session non-attendance varies
according to which session of the week the patient misses. The impact of this on subsequent hospitalization and
mortality is unknown.
Methods: The ARO cohort study prospectively collected data from hemodialysis patients across 15 European
countries on demography, comorbidity, laboratory, hospitalisation, mortality and individual hemodialysis sessions
from 2007 to 2014. Event rates for death and hospitalisation according to dialysis day of the week were calculated
for patients who attended the three previous scheduled hemodialysis sessions, who then on the next scheduled
dialysis day either attended or did not attend. The hazard ratio for these events following non-attendance for the
first compared to the second dialysis session of the week was estimated using Cox proportional hazards model
adjusted for patient demographics.
Results: 3.8 million hemodialysis sessions in 9397 patients were analysed. The non-attendance rates for Monday/
Wednesday/Friday sessions were 0.8, 0.9% & 1.4% respectively, and for Tuesday/Thursday/Saturday sessions were
0.6, 1.0% & 1.2% respectively. Compared to those who attended, for the 48–72 h between non-attendance and the
next scheduled haemodialysis session, mortality significantly increased from 4.86 to 51.9/100 pt-yrs and
hospitalisation increased from 0.58 to 2.1/yr. As time from the two-day break increased, the risk associated with
non-attendance lessened: compared to missing the second hemodialysis session, missing the first session had a
hazard ratio for mortality of 2.04 (95% CI 1.27–3.29), and for hospitalisation 1.78 (95% CI 1.29–2.47). In patients who
attended their scheduled dialysis session and the three preceding, after the two-day break there were absolute
increases in mortality (8.3 vs. 4.9/100 pt-yrs) and hospitalisation (1.0 vs. 0.6/yr for the rest of the week) comparable
to previous studies.
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Conclusions: In addition to hospitalisation and mortality increases seen after the two-day break, additional harm
may be manifested in the greater increases in mortality and hospitalisation observed after non-attendance for the
first hemodialysis session after the two-day break compared to missing other sessions.
Keywords: Hemodialysis, Adherence, Compliance, Interdialytic interval, Hospitalisation, Mortality
Background
Non-attendance for dialysis is common, with the pro-
portion of sessions affected between 0.6% in Europe and
Japan to 7.9% in the United States [1]. Non-adherence is
often assumed to reflect underlying psychological factors
[2], but the evolution of acute illness, complications with
dialysis access, rescheduling for planned admissions and
holidays also lead to changes in the dialysis schedule [3].
These mechanisms may be a partial explanation for the
association between non-attendance and hazard ratios
for hospitalisation of 1.13 to 3.98 and medium-term
mortality of 1.33 to 2.36 [1, 4–6]. However, all but one
of these studies recruited patients after the non-adherent
session of interest and/or analysed the occurrence of
endpoints months to years afterwards, thereby reflecting
the risk of non-adherent phenotype rather than the
short-term risk of skipping a HD session.
Over 95 % of patients worldwide receiving (HD) for
treatment of kidney failure are offered three dialysis ses-
sions per week, with the most commonly assigned
schedules being Monday/Wednesday/Friday (MWF) and
Tuesday/Thursday/Saturday (TTS) [7]. The HD session
before the two day break usually falls before a weekend
on a Friday or Saturday, when patients are likely to en-
gage in activities which they may prioritise over attend-
ing for dialysis. Non-attendance for the first HD session
of the week means that the immediate period after non-
attendance is associated with the highest exposure to
fluid, potassium and uraemic toxins, and non-attendance
for the third HD session of the dialysis week potentially
results in the extension of the two-day break to a four-
day break. The variation in the harm caused by non-
attendance in relation to the length of the preceding
interdialytic interval is not known. Furthermore, to date
the large studies that have explored the harm associated
with the “long gap” have used a range of approaches to
determine the patient’s HD schedule [8–10] and have
not ensured patients reliably attended. To explore these
issues, we examined data from a large European cohort
of in-centre HD patients on three times-a-week sched-
ules [11] who attended their scheduled dialysis fully.
Methods
This study explored the hypothesis that there may be
differential risk of mortality and hospitalisation following
non-attendance according to the interdialytic interval.
Study population
The Analyzing Data, Recognizing Excellence and Opti-
mizing Outcomes (ARO) cohort study contains anon-
ymised longitudinal individual-level data for patients
starting HD who were enrolled at one of the 312 Frese-
nius Medical Care (FMC) facilities across 15 European
countries between 2007 and 2009 and followed up until
the end of 2014. Data on demography, comorbidity, la-
boratory, hospitalisation, mortality and individual HD
sessions were captured prospectively [12]. The study co-
hort used for this analysis was limited to patients who
were prescribed three times a week HD, who had sur-
vived more than 90 days after starting HD, had HD ses-
sion and laboratory data available at any time-point
during the study, and in whom a MWF or TTS schedule
could be identified. They were censored following trans-
plantation, change in dialysis modality, transfer to a
non-FMC facility or lost to follow-up.
Hemodialysis schedule, non-attendance, hospitalisation
and mortality
In patients who were prescribed three times a week HD,
for each day of follow-up time we reviewed the preced-
ing seven days to identify on which days HD was con-
ducted, enabling us to identify MWF and TTS
schedules. We did not analyse patients receiving the less
common Tuesday/Thursday/Sunday schedule, as TTS
patients could miss a Saturday session, and be offered a
Sunday session instead. This would be interpreted as a
Tuesday/Thursday/Sunday schedule and would artifi-
cially lower the rate of non-attendance on Saturday in
TTS patients. The first HD session after a scheduled
long interval was defined as the first day of the dialysis
week, this being Monday for patients dialysing MWF
and Tuesday for patients dialysing TTS.
We examined each scheduled dialysis day, first con-
firming that the three preceding scheduled MWF or
TTS sessions had been attended. We then assessed for
non-attendance determined by the absence of a recorded
pre-dialysis blood-pressure, pre-dialysis weight and dia-
lysis treatment time. From these we excluded dialysis
days and associated events in patients who were hospi-
talized or died on the identified day of non-attendance
as these events which prevent attendance would not rep-
resent non-adherence. We also excluded patients who
had been discharged from hospital in the preceding
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seven days and those who had an un-scheduled HD ses-
sion on the preceding day potentially resulting in a tem-
porary or permanent change to their dialysis schedule.
Patients who had missed an HD session but then return
to a MWF or TTS pattern then re-entered the data set
from this point. A record of hospital admission is made
by the clinic staff and those are required when a patient
missed at least one treatment. The analysis was limited
to hospitalizations lasting longer than one night, which
do not involve routine dialysis vascular access care
(International Classification of Disease Version 10 Codes
pertaining to: adjustment and management of vascular
access device, arteriovenous fistula, mechanical compli-
cation of vascular dialysis catheter, mechanical complica-
tion of other vascular grafts, other complications of
cardiac and vascular prosthetic devices, implants and
grafts, preparatory care for dialysis).
Statistical analysis
Although all follow-up time on 3xW HD was considered
in our analysis, in order to facilitate comparisons to
other studies of non-adherence, the demographics of the
cohort are reported stratified by whether the patient did
not attend a HD session during the first 4 months of the
study. We report the crude non-attendance as a propor-
tion, the numerator being the number of missed sched-
uled HD sessions in non-hospitalised patients, who had
an established MWF or TTS schedule and who have
attended all three preceding scheduled HD sessions. The
denominator was the number of scheduled HD sessions
in the above patients and setting. These crude propor-
tions are reported across dialysis days and between
schedules, using multivariate logistic regression to deter-
mine if significant variation existed.
In order to quantify the per-day rates of hospitalisation
and mortality and their relationship to the dialysis
schedule we calculated hospitalisation (per patient year)
and mortality (per 100 patient years) event rates for each
individual dialysis day in individuals who attended the
three preceding scheduled dialysis. These events are re-
ported separately for the two dialysis schedules day and
if the patient attended or did not attend the next sched-
uled dialysis session. For patients classified as not at-
tending this HD session we reported hospitalisation and
mortality rates for each day between the day after the
missed session and the day of the next scheduled HD
session (2 to 3 days), as shown in Fig. 1. Hospitalisation
and mortality rates are effectively zero on the day of
non-attendance due to our exclusion criteria. Event rates
and associated confidence intervals around mortality
and hospitalisation rates were estimated using the Pois-
son distribution, calculated by dividing the total number
of events divided by the total patient time over which
these events occurred (stratified by dialysis day and at-
tendance). Although this does not fully capture within-
and between-patient variation, we demonstrate that this
is statistically appropriate in our supplementary mate-
rials. We fitted multivariate time-varying single event
(mortality endpoints) and multiple event (hospitalization
endpoints) Anderson and Gill Cox regression models
[13]. In addition to being able to handle multiple events,
The Anderson and Gill cox extension has been shown to
be robust where discontinuous patient follow-up time is
present (such as while a patient is hospitalized or during
extended non-adherence) [14]. In patients who attended,
this follow-up time was one day, allowing us to estimate
the risk of hospitalisation for each individual day of the
dialysis week. In those who did not attend, follow-up
Fig. 1 Illustration of the identification of complete attendance for three scheduled hemodialysis sessions, non-attendance, and subsequent
mortality and hospitalisation
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was counted from the day after the non-attended session
until the next scheduled HD session (two or three days
depending on the session missed, Fig. 1). All regression
models used the second HD day (Wednesday or Thurs-
day in MWF and TTS respectively) as a reference. In
order to compare the risk of hospitalisation and mortal-
ity between attenders and non-attenders, we used the
second dialysis day in those who attended as the refer-
ence day. All multivariate models were adjusted for age,
gender, comorbidity (previous acute ischemic heart dis-
ease event, congestive cardiac failure, chronic obstructive
pulmonary disease, cerebrovascular disease, diabetes,
arrythmias, gastrointestinal bleeding, liver disease, other
cardiac disease, peripheral vascular disease, cancer), time
on dialysis and vascular access type. We did not adjust
for dialysis session or laboratory variables as they are po-
tentially in the causal pathway between non-attendance
and our endpoints of interest [15]. We account for clus-
tering of repeated observation and events in our hospi-
talisation analyses with a robust sandwich variance
estimator.
The proportion of sessions fully attended prior to hos-
pitalisation was estimated to determine the proportion
of patients deviating from their schedule prior to admis-
sion: the numerator being the number of hospitalisations
in which patients deviated from their scheduled HD ses-
sions prior to hospitalisation, the denominator being all
hospitalisations in three times a week patients on estab-
lished MWF or TTS schedules.
We conducted the following sensitivity analyses. To
explore if rescheduled or emergency dialysis identified
through an FMC provider altered the variation in out-
comes according to dialysis day of the week, we cen-
sored at the time when rescheduled dialysis was
delivered. In an attempt to identify facility-directed dia-
lysis rescheduling (e.g. moving from MWF to TTS) as an
explanation for variation in non-attendance, we excluded
non-attended sessions which preceded a new three times
a week schedule that persisted for two weeks. All ana-
lyses were conducted in R version 3.4.4.
Results
From the 11,211 patients in the ARO cohort, 9397 were
identified as receiving three times a week HD, could be
assigned a MWF or TTS schedule, had complete set of
covariate data and had survived 90 days from entry into
the study. The overall mortality rate was 11.0 deaths per
100 patient years, and the emergency hospitalisation rate
was 0.66 per patient year. Figure 2 summarises the ana-
lysis of the 3.8 million HD sessions with full attendance
Fig. 2 Summary of the number of patients, follow-up time, dialysis sessions and analytical methods employed
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(all three scheduled haemodialysis sessions prior to the
day of analysis), representing 1.34 million weeks of treat-
ment. There were 1376 deaths and 15,317 hospitalisa-
tions in the follow-up period following full attendance.
Dialysis session non-attendance by schedule and day of
the week
Following three consecutive attended HD sessions, the
proportion of scheduled HD sessions that were not
attended was 1.0% (36,236 of 3,783,134 sessions ana-
lysed). The characteristics of patients who attended
compared to those did not attend one or more sessions
during the first four months of the study are detailed in
Table 1 and highlight that younger, male patients with
less comorbidity were more likely not to attend a HD
session.
A higher proportion of the third HD session were
missed in both MWF and TTS schedules (Table 2).
Compared to the middle dialysis day, the odds of miss-
ing the first and third dialysis days in MWF patients
were 0.83 (95% CI 0.80–0.86) and 1.55 (95% CI 1.51–
1.61) respectively. In TTS patients these were 0.63 (95%
0.61–0.67) and 1.28 (95% CI 1.24–1.34). Overall the pro-
portion of sessions that were non-attended was similar
across countries, but some variation in which session of
the dialysis week was most commonly non-attended was
evident (Supplementary Figure 1 in Additional File 1). In
these patients scheduled to receive dialysis three times a
week, 20.4% of emergency hospitalisations were pre-
ceded by a deviation from their three times a week
schedule (3776/18,546) with no significant difference be-
tween MWF and TTS regimens (20.7 and 20.1% respect-
ively, P = 0.32).
Hospitalisation and mortality immediately following non-
attendance
Overall, between a missed HD session and the next
scheduled HD session, the mortality rate was 51.9 per
100 patient years (95% CI 43.5–61.4), and hospitalisation
rate was 2.13 per patient years (95% CI 1.95–2.32), com-
pared to 4.86 (95% CI 4.6–5.1) and 0.58 (95% CI 0.57–
0.59) during the same period in those who attended the
HD session. The variation in hospitalisation and mortal-
ity events and associated event rates, stratified by attend-
ance or non-attendance across the dialysis week is
reported in Table 2. These rates were greater if the ses-
sion missed was the first after the two-day break (Table
2): compared to missing the second session of the dialy-
sis week, the hazard ratio for mortality after missing the
first HD and the third HD were 2.04 (95% CI 1.27–3.29)
and 0.71 (95% CI 0.44–1.14) respectively. For hospital-
isation these were 1.78 (95% CI 1.29–2.47) and 0.92
(95% CI 0.67–1.28) respectively. The variation in these
event rates and the multivariate adjusted hazard ratio
are shown alongside findings from patients with perfect
attendance in Figs. 3 and 4. When performing these
Table 1 Patient characteristics according to non-attendance in the first 4 months of the study
Attended (83.3%) Non-Attended (16.7%) P
n 7467 1501
Age (mean (sd)) 64.83 (14.72) 61.68 (15.16) < 0.001
Interdialytic weight gain (Kg) 1.58 (1.06) 1.56 (1.10) 0.367
Systolic Blood Pressure (mmHg) 137.79 (24.15) 137.55 (24.72) 0.722
Diastolic Blood Pressure (mmHg) 71.34 (13.91) 73.43 (14.00) < 0.001
Male (%) 4532 (60.7) 881 (58.7) 0.157
Dialysis Catheter 3408 (45.6) 743 (49.5) 0.007
Acute ischemic cardiac event 1107 (14.8) 199 (13.3) 0.126
Cancer 569 (7.6) 105 (7.0) 0.433
Cardiac Failure 1111 (14.9) 185 (12.3) 0.011
Chronic Obstructive Pulmonary Disease 461 (6.2) 60 (4.0) 0.001
Cerebrovascular Accident 672 (9.0) 93 (6.2) < 0.001
Depression 112 (1.5) 21 (1.4) 0.859
Diabetes 2581 (34.6) 509 (33.9) 0.647
Dysarrythmia 672 (9.0) 98 (6.5) 0.002
Gastrointestinal Bleeding 98 (1.3) 19 (1.3) 0.984
Liver Disease 197 (2.6) 38 (2.5) 0.883
Other Cardiac Disease 51 (0.7) 10 (0.7) 1.000
Peripheral Vascular Disease 808 (10.8) 143 (9.5) 0.150
429 patients (4.6%) excluded from table due to missing blood pressure and weight data during the first 4 months of the study
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analyses on individual schedules, this association failed
to meet statistical significance in MWF patients but was
evident in TTS patients (Fig. 5a-b).
Hospitalisation and mortality across the dialysis week in
patients who attended their scheduled dialysis session
In patients who attended their scheduled dialysis session
and the three preceding HD sessions, mortality was
greatest on the day of the first HD session after the long
interdialytic interval in both MWF and TTS schedules
(Figs. 3 and 4). Mortality rate was 8.3 per 100 patient
years after the two-day break compared to 4.9 per 100
patient years for the rest of the week (adjusted hazard
ratio 1.71, 95% CI 1.50–1.96). Similarly, hospitalisation
in patients who attended their scheduled HD session
was greatest in patients after the two-day break (Fig. 4):
0.96 hospitalisations per patient year compared to 0.51
for the rest of the week (adjusted hazard ratio 1.87, 95%
CI 1.79–1.95).
Sensitivity analyses
Our sensitivity analysis which censored on the day a
rearranged dialysis session was performed prior to the
next scheduled dialysis did not show a significant differ-
ence in the hazard of mortality following non-
attendance according to which day of the dialysis week
was not attended, however hospitalisation in TTS pa-
tients after non-attendance for the third session did in-
crease (Figure S2 in Additional File 1). Excluding non-
attended dialysis sessions which preceded a change in
Table 2 Mortality and hospitalisation events and associated rates, stratified by hemodialysis attendance. Events following non-
attended sessions are reflected in the columns of subsequent haemodialysis days (e.g. missing Monday’s HD session influences
Tuesday and Wednesday’s events)
Mon/Wed/Fri Schedule Mon Tue Wed Thu Fri Sat Sun
Non-Attendance rate (%) 0.77 NA 0.96 NA 1.44 NA NA
Attended Admissions (n) 1866 1314 1409 956 1116 432 557
Attended Admit Rate
(annualised)
0.94 (0.90–0.99) 0.66 (0.63–0.70) 0.71 (0.68–0.75) 0.48 (0.45–0.51) 0.57 (0.54–0.60) 0.22 (0.20–0.24) 0.28 (0.26–0.30)
Attended deaths (n) 150 70 111 82 95 67 78
Attended Death Rate
(/100 pt. yrs)
7.6 (6.43–8.91) 3.52 (2.74–4.45) 5.63 (4.63–6.78) 4.12 (3.28–5.12) 4.84 (3.91–5.91) 3.39 (2.63–4.31) 3.9 (3.08–4.86)
Attended Days at risk 720,744 726,084 719,809 725,761 716,707 721,293 730,785
Non-Attended Admissions (n) 54 50 37 49 41 38 34
Non-Attended Admit Rate
(annualised)
1.95 (1.47–2.54) 3.44 (2.56–4.54) 2.57 (1.81–3.54) 2.67 (1.97–3.53) 2.25 (1.61–3.05) 1.37 (0.97–1.89) 1.23 (0.85–1.72)
Non-Attended deaths (n) 11 13 8 12 8 10 3
Non-Attended Death Rate
(/100 pt. yrs)
39.4 (19.7–70.6) 89 (47.4–152.3) 54.9 (23.7–108.3) 65.0 (33.6–113.5) 43.6 (18.8–85.8) 35.9 (17.2–65.9) 10.8 (2.2–31.5)
Non-attended Days at risk 10,107 5300 5264 6707 6655 10,096 10,087
Tue/Thu/Sat Schedule Mon Tue Wed Thu Fri Sat Sun
Non-Attendance rate (%) NA 0.58 NA 0.98 NA 1.18 NA
Attended Admissions (n) 1132 1638 1115 1207 781 822 425
Attended Admit Rate
(annualised)
0.67 (0.63–0.71) 0.99 (0.94–1.04) 0.66 (0.62–0.7) 0.73 (0.69–0.77) 0.46 (0.43–0.5) 0.5 (0.46–0.53) 0.25 (0.23–0.28)
Attended deaths (n) 106 152 61 83 59 88 40
Attended Death Rate
(/100 pt. yrs)
6.28 (5.14–7.6) 9.16 (7.76–10.74) 3.63 (2.78–4.66) 4.99 (3.98–6.19) 3.51 (2.67–4.53) 5.3 (4.25–6.53) 2.39 (1.71–3.26)
Attended Days at risk 615,821 605,425 613,691 606,784 613,588 605,619 610,508
Non-Attended Admissions (n) 43 28 60 25 46 16 26
Non-Attended Admit Rate
(annualised)
2.24 (1.62–3.02) 1.46 (0.97–2.12) 6.41 (4.89–8.24) 2.71 (1.76–4.01) 2.88 (2.11–3.84) 1.01 (0.58–1.64) 1.36 (0.89–1.99)
Non-Attended deaths (n) 9 6 13 15 11 7 8
Non-Attended Death Rate
(/100 pt. yrs)
46.6 (21.3–88.4) 31.1 (11.4–67.6) 138.4 (73.7–236.6) 159.9 (89.5–263.8) 68.7 (34.3–123) 44 (17.7–90.6) 41.4 (17.9–81.5)
Non-attended Days at risk 7053 7050 3429 3423 5842 5812 7059
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schedule persisting for two weeks resulted in a reduction
in the variation in non-attendance across the dialysis
week, however relative to missing the second dialysis
session, greater increases in hospitalisation and mortality
after missing the first session persisted (Figure S2 in
Additional File 1).
Discussion
There is mounting evidence of the size and mechanism
of harm from the two day break in three times a week
dialysis. We were able to use session-level data from
9397 patients spanning fifteen countries to show that
this harm expands to the period immediately after non-
Fig. 3 The mortality rate in 100 patient years (a) and associated multivariate hazard ratio (b) according to dialysis schedule and day of the week
for patients who attended and did not attend a HD session. For non-attended sessions, the hazard for mortality is depicted for the days between
the missed session and next scheduled session
Fig. 4 The hospitalisation rate in patient years (a) and associated multivariate hazard ratio (b) according to dialysis schedule and day of the week
for patients who attended and did not attend a HD session. For non-attended sessions, the hazard for mortality is depicted for the days between
the missed session and next scheduled session
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attendance with greater increases in hospitalization and
mortality after the long interdialytic interval. Non-
attendance was greatest for sessions immediately prior
to or scheduled for a weekend day, and even after prior
full HD attendance three times a week, there are in-
creases in mortality and hospitalisation endpoints after
the long interdialytic interval.
Due to the variation in definitions for adherence in the
published literature, the assessment of non-adherence
being performed on the period immediately prior to the
patient consenting into observational studies introducing
a range of biases [4], and the variation in the follow-up
period over which the endpoint is assessed, direct com-
parison between studies is challenging. Non-adherence
according to dialysis day of the week, when reported,
has varied to a greater extent in TTS patients [5, 16].
The comparable nature of non-attendance between the
two schedules may reflect methodological issues, how-
ever accounting for changes in HD schedule and rear-
ranged dialysis did not alter the variation in hazard for
both our endpoints following non-attendance across the
dialysis week. The change in the proportion non-
attended on Saturdays in TTS patients following adjust-
ment for rescheduling is logical as a patient may want to
attended weekend activities. We found a relative risk of
hospitalisation after non-attendance similar to some
studies [6], higher than others, and this is likely be due
to follow-up starting some time after the non-adherent
session and longer follow-up spanning multiple sub-
sequent scheduled sessions [1, 4].
In limiting our analysis to patients with full attend-
ance, we demonstrate how attendance alters mortality
and hospitalisation rates. USRDS and the UK Renal
Registry data have shown hospitalisation and mortality
event rates approximately twice those observed in our
study on the first and second HD days [9, 10]. These dif-
ferences may be due to the methods used to determine
the dialysis regimen: The USRDS study determined dia-
lysis schedule by combining the number of dialysis ses-
sions reported per week, with the day of the week the
pre-dialysis urea sample was taken [9]. The UK Renal
Registry study used individual sessions reported through
hospital activity data to assign HD schedules, but due to
incomplete dialysis session capture, carried forward the
previous schedule when the pattern of attendance devi-
ated [10], and this study shows that ahead of hospitalisa-
tion 20.4% of patients deviate from the three times a
week schedule. When exploring the two day break effect,
Fig. 5 Summary of non-attendance and the subsequent mortality and hospitalisation rates according to dialysis session non-attended. Black:
Monday/Wednesday/Friday patients, Grey: Tuesday/Thursday/Saturday patients
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absolute differences in event rates comparing the first
and second dialysis days across all studies including ours
seem comparable.
We cannot determine from these observational data
with certainty that missed sessions contribute causally to
hospitalisation and dialysis. The relationship could be
explained by a confounding factor, such as acute illness
which both prevents attendance for scheduled dialysis
and leads to hospital admission or death, or that the true
timing of death was before the non-attended session.
However, it is difficult to explain how these mechanisms
which could bias our findings would vary across the dia-
lysis week, since the prevalence or severity of acute ill-
ness itself is unlikely to vary to the degree required to
explain our observations. This variation could plausibly
represent a manifestation of ongoing harm caused by
the two-day break manifest beyond the first session of
the dialysis week. Our study does not attempt to shed
additional light on the likely mechanisms of harm asso-
ciated with the two-day break, but it does support the
conclusion that the long gap is followed by increases in
mortality and hospitalisation.
Our study has several notable strengths. The most im-
portant being that through utilisation of session level data,
we were able to confidently assign and ensure that pa-
tients received the scheduled three times a week dialysis
for the preceding week in both non-adherent and fully
attended analyses. Our analysis makes it unlikely that vari-
ation in non-attendance across the dialysis week, with
greater non-attendance before the two day break, explains
increases in events after the long interdialytic interval. We
may also have provided a more accurate measure of the
increased risk associated with the long gap than previous
studies. Our study is limited by the fact that we have
adopted a definition of non-attendance based on the avail-
able data, although our rates are similar to those reported
by others [6]. To improve our non-attendance data we
would have had some objective assessment by dialysis staff
as to whether the non-attendance was for medical or lo-
gistical reasons [3] or driven by attitudes surrounding the
importance of the treatment relative to other events oc-
curring in the patient’s life [2], which may persist post-
transplantation and influence graft outcomes [17]. These
attitudes may well be informed by the patients’ own beliefs
as to what represents a safe interdialytic interval. Like
others investigators, we are unable to exclude the fact that
non-attendance is the manifestation of death in the pre-
ceding 24 h [6], but include these analyses to understand
more fully the two day break on mortality. We are
confident about our capture of hospitalisations which
are similar to recently published rates from other studies
[4], although after non-attendance these events are too
few for us to look at admission causes and postulate
mechanisms.
Conclusions
From our study, we suggest how a clinician should con-
sider the potential implications of a patient not attend-
ing a haemodialysis session should account for which
session is missed. Our data also indicate that even fol-
lowing efforts to reschedule dialysis in the 24–48 h after
non-attendance, a greater hazard for mortality and
hospitalization persist after non-attendance for the HD
session after the long interdialytic interval. In fact, the
extension of the interdialytic interval from one to two
days, even in in patients who attend regularly, is associ-
ated with poor outcomes. We hope that our data will
help physicians and nurses counselling patients regard-
ing the potential harms of missed dialysis sessions. We
believe that with accumulating observational data sug-
gesting clinical harm associated with the long interdialy-
tic interval observational analysis of practices excluding
it should inform the design of a clinical trial of dialysis
regimens with and without a two-day gap.
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